Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Total Non-Current Liabilities for 9 years, with the latest figure at $194.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 42.12% year-over-year to $194.3 million; the trailing twelve-month figure through Mar 2026 stood at $194.3 million (up 42.12% YoY), and the FY2025 full-year result was $177.5 million, up 26.52% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $194.3 million, up from $177.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $194.3 million in Q1 2026, with the low at $50.9 million in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $106.8 million across 5 years, with a median of $85.9 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 95.45% — and 2023, when it declined 21.05%.
• Kiniksa Pharmaceuticals International's Total Non-Current Liabilities stood at $61.7 million in 2022, then jumped by 38.81% to $85.6 million in 2023, then jumped by 63.85% to $140.3 million in 2024, then climbed by 26.52% to $177.5 million in 2025, then gained by 9.45% to $194.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $194.3 million (Q1 2026), $177.5 million (Q4 2025), and $162.4 million (Q3 2025), per Business Quant data.